Although several NAMPT inhibitors (FK866, CHS-828, and EB-1627) have been introduced into the clinic, they ultimately failed in phase II clinical trials due to dose-limiting toxicities, including thrombocytopenia and retinal and cardiac toxicity.47 This evidence concerns the gene NAMPT and Thrombocytopenia.